Symbols

TBIO(Delisted)

Telesis Bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

EPS Beats Expectation

Bullish Abandoned Baby

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TBIO

Telesis Bio Inc.

messenger RNA or mRNA therapy company

Industry

Established Date

03/24/2011

Listing Date

06/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

137

Fiscal Year Ends

12-31

Website

www.telesisbio.com

Security Type

Common stock

Office address

10431 Wateridge Circle, Suite 150, San Diego, CA, 92121

Business

Introduction

Telesis Bio Inc., incorporated in Delaware on March 24, 2011 as Synthetic Genomics Solutions, Inc., is a wholly-owned subsidiary of Synthetic Genomics, Inc. On February 26, 2013, the company changed its name to SGI-DNA, Inc., and on March 31, 2020, it changed its name to Codex DNA, Inc. Telesis Bio empowers scientists to create novel, synthetic biology-enabled solutions to many of humanity's greatest challenges. As the inventor of the industry-standard Gibson Assembly method and the first commercially automated desktop DNA and mRNA synthesis system, Telesis Bio is enabling fast, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Therefore, DNA and RNA synthesis with little error is available on a large scale in days and hours rather than weeks or months. Scientists around the world are using this technology in the laboratory to accelerate the design-build-test paradigm of new, high-value products for precision medicine, biologic drug discovery, vaccine and treatment development, genome editing, and cell and gene therapy.

Company Financials

EPS

TBIO has released its 2024 Q1 earnings. EPS was reported at -5.52, versus the expected -0.23, missing expectations. The chart below visualizes how TBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TBIO has released its 2024 Q2 earnings report, with revenue of 1.55M, reflecting a YoY change of -77.87%, and net profit of -12.59M, showing a YoY change of -51.86%. The Sankey diagram below clearly presents TBIO's revenue sources and cost distribution.